Condition 1: Other noninflammatory disorders of uterus, except cervix. Condition 2: Endometrial glandular hyperplasia. Condition 3: Endometrial adenomatous hyperplasia. Other noninflammatory disorders of uterus, except cervix Endometrial glandular hyperplasia Endometrial adenomatous hyperplasia
Conditions
Interventions
Intervention 1: Intervention group 1: administration of metformine, 1000 miligram daily for 4 weeks followed by 1500 miligram daily for 8 weeks. Intervention 2: Intervention group 2: administratio
Treatment - Drugs
Intervention group 1: administration of metformine, 1000 miligram daily for 4 weeks followed by 1500 miligram daily for 8 weeks.
Intervention group 2: administration of mejestrol, 40 miligram daily for 12 weeks.
Sponsors
Vice chancellor for research ,Iran University of Medical Sciences.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: ultrasound which confirms endometrial thickening and simple endometrial hyperplasia without atypia in endometrial sampling. exclusion criteria: history of intolerance to metformine or mejestrol; using metformine during previous 6 months; history of hepatic or renal disorders; plasma glucose of less than 60 mg/dl or more than 200 mg/dl ; current using of any medication, any gynecologic neoplasia; using any kind of hormones.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endometrial hyperplasia. Timepoint: 3 months after treatment. Method of measurement: endometrial sampling. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Kashanian
Iran University of Medical Sciences
Outcome results
None listed